Federation Bio

6 articles about Federation Bio

• MD Anderson and Federation Bio Announce Collaboration to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers

  2/1/2023

  The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a complex, synthetic microbial consortium with the goal of expanding the number of cancer patients who respond to immunotherapy.

• Federation Bio Administers First Dose in Phase 1 Clinical Trial Evaluating Investigational Bacterial Cell Therapy

  12/8/2022

  Federation Bio, a biotechnology company pioneering bacterial cell therapies, today announced that investigators have administered the first dose in a Phase 1 clinical study evaluating the company's lead therapeutic candidate, FB-001, for the treatment of enteric hyperoxaluria.

• 

  Voyager Lands Former Biogen Exec Al Sandrock

  2/3/2022

  Alfred Sandrock Jr., the former head of research and development at Biogen, has taken a position on the board of directors of Cambridge, Mass.-based Voyager Therapeutics.

• Federation Bio Expands Leadership Team To Support Continued Advancement of Engineered Bacterial Cell Therapies

  11/30/2021

  Federation Bio, a biotechnology company pioneering engineered bacterial cell therapies, announced the appointment of two new members to its executive team.

• 

  BioSpace Movers & Shakers, Oct. 9

  10/9/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies

  10/6/2020

  -- Federation Bio is developing microbial therapies comprising naturally occurring and genetically modified bacterial strains -- Horizons Ventures led the financing, joined by Seventure Partners/Health for Life Capital, as well as existing investors, including Venrock and Altitude -- Company appoints Dr. Emily Drabant Conley chief executive officer and expands board of directors to include Dr. Conley and Dr. John Stuelpnagel